Dr. Zalupski on Implications of the KEYNOTE-061 Trial in Gastric Cancer

Mark M. Zalupski, MD
Published: Tuesday, May 28, 2019



Mark M. Zalupski, MD, professor of medicine at the University of Michigan School of Medicine, discusses the clinical implications of the phase III KEYNOTE-061 trial in gastric cancer.

The purpose of the trial was to demonstrate the value of PD-1 antibody therapy with pembrolizumab (Keytruda) in patients with metastatic gastric cancer, says Zalupski. However, the study did not demonstrate that immunotherapy was more efficacious than chemotherapy in the second-line setting. This was especially true for unselected patients and for patients who were PD-L1–positive on staining. However, a small fraction of patients did appear to have some benefit from PD-1 antibody therapy, he adds.

For patients who have high combined positive score or microsatellite instability–high tumors, anti–PD-1 therapy may be useful. Additional research into combining immunotherapy with chemotherapy in the second-line setting may also prove beneficial, although ongoing trials will have to further define its use and value, concludes Zalupski.
SELECTED
LANGUAGE


Mark M. Zalupski, MD, professor of medicine at the University of Michigan School of Medicine, discusses the clinical implications of the phase III KEYNOTE-061 trial in gastric cancer.

The purpose of the trial was to demonstrate the value of PD-1 antibody therapy with pembrolizumab (Keytruda) in patients with metastatic gastric cancer, says Zalupski. However, the study did not demonstrate that immunotherapy was more efficacious than chemotherapy in the second-line setting. This was especially true for unselected patients and for patients who were PD-L1–positive on staining. However, a small fraction of patients did appear to have some benefit from PD-1 antibody therapy, he adds.

For patients who have high combined positive score or microsatellite instability–high tumors, anti–PD-1 therapy may be useful. Additional research into combining immunotherapy with chemotherapy in the second-line setting may also prove beneficial, although ongoing trials will have to further define its use and value, concludes Zalupski.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x